| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $9.4M | -39.0% |
| SG&A Expense | $6.2M | -14.7% |
| Operating Income | -$15.6M | +31.3% |
| Pre-tax Income | -$15.5M | +33.9% |
| Net Income | -$15.5M | +33.9% |
| EPS (Basic) | -$10.20 | +60.8% |
| EPS (Diluted) | -$10.20 | +60.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $12.2M | — |
| Current Assets | $12.7M | +2088.2% |
| Total Assets | $14.9M | +325.7% |
| Current Liabilities | $5.0M | -51.4% |
| Total Liabilities | $7.4M | -28.5% |
| Stockholders' Equity | $7.5M | +208.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$18.5M | -22.7% |
| Capital Expenditures | $212K | -5.5% |
| Investing Cash Flow | -$212K | +5.5% |
| Financing Cash Flow | $30.8M | +209.6% |
| Free Cash Flow | -$18.7M | -22.3% |